• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002107.SZ
Share

Shandong Wohua Pharmaceutical Co., Ltd. Stocks

CN¥ 6.73Last Updated 15.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 534.11M

CN¥ 6.73
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shandong Wohua Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the development, production, and distribution of a broad array of medicinal products across the country. The company's extensive product portfolio addresses various therapeutic categories. Key offerings include Xinkeshu tablets, Naoxueshu oral solutions, and Tongluo Huayu capsules, which are specifically formulated for cardiovascular and cerebrovascular health. Beyond these, Shandong Wohua also supplies medications for respiratory conditions, drugs targeting the urinary and digestive systems, anti-rheumatic treatments, and sedative agents. Furthermore, it provides specialized pharmaceuticals tailored for women and children. Headquartered in Weifang, China, the company operates as a subsidiary under the ownership of Beijing Zhongzheng Wanrong Investment (Group) Co., Ltd.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, 'expens

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 18:44

Kaspi.kz has completed the acquisition of Turkey's Rabobank

15.07.2026 18:25

Shares of a mid-cap company that develops chip-testing solutions have skyrocketed. Why?

15.07.2026 18:04

Wholesale prices in the U.S. fell in June—a development the market did not expect

15.07.2026 17:30

Assets under management at BlackRock exceeded $15 trillion for the first time

15.07.2026 17:00

OpenAI's first device will be a "smart speaker." Will this create competition for Apple?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026